None
Quote | Forty Seven Inc. (NASDAQ:FTSV)
Last: | $95.51 |
---|---|
Change Percent: | 0.05% |
Open: | $95.46 |
Close: | $95.51 |
High: | $95.515 |
Low: | $95.46 |
Volume: | 693,725 |
Last Trade Date Time: | 04/06/2020 04:46:57 am |
News | Forty Seven Inc. (NASDAQ:FTSV)
Trillium Therapeutics has an encouraging pipeline with key differentiators that have attracted recent investor interest. The 2 major candidates, TTI-621 & 622 have shown monotherapy activity in a breadth of haematologic cancers as CD47 targeting drugs. Shares have rallied over...
Jounce Therapeutics ( JNCE ) is a small biotechnology company focused on the rapidly expanding industry of immuno-oncology. Armed with a productive drug discovery platform, a unique mid-stage lead candidate in lung cancer, and a penchant for striking lucrative deals with big pharma, the future...
Message Board Posts | Forty Seven Inc. (NASDAQ:FTSV)
Subject | By | Source | When |
---|---|---|---|
Thanks for the tip. I look into him. | Cosa | investorshub | 01/14/2020 11:30:57 PM |
Looks like Terry Chrisomalis should be followed. | Glider549 | investorshub | 12/27/2019 6:55:04 PM |
wow still going... | Cosa | investorshub | 12/23/2019 8:25:14 PM |
Just created this board, this ticker has been | Cosa | investorshub | 12/12/2019 8:53:29 PM |
News, Short Squeeze, Breakout and More Instantly...
The ongoing COVID-19 pandemic has caused significant disruptions to the global economy, as well as grievances for families witnessing their loved ones die from the virus. Fortunately, there's finally a light at the end of the tunnel as one investigative treatment has revealed potential efficacy ...
For years, Gilead Sciences ' (NASDAQ: GILD) stock price has been rather disappointing for investors hoping for long-term capital appreciation. While shares do boast an impressive 3.63% dividend yield, the company's revenues have experienced an enormous decline from 2015 onwards, falling over ...
Shares of Forty Seven (NASDAQ: FTSV) climbed 64.5% in March, according to data from S&P Global Market Intelligence . The immuno-oncology specialist's stock skyrocketed early in the month after it was announced that the company was on track to be purchased by Gilead Sciences...